Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. 2008

Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
Department of Physiology, Toho University School of Medicine, 5-21-16, Omori-nishi, Ota-ku, Tokyo 143-8540, Japan.

The present study re-evaluated an existing notion that serotonin (5-hydroxytryptamine; 5-HT) could not cross the brain to the circulating blood via the blood-brain barrier (BBB). To elevate brain 5-HT alone, 5-hydroxytryptophan (5-HTP; 30-75 mg/kg) was administrated intravenously to anaesthetized rats that had undergone gastrointestinal and kidney resections along with liver inactivation (organs contributing to increasing blood 5-HT after 5-HTP administration). A microdialysis method and HPLC system were used to determine the brain 5-HT levels in samples collected from the frontal cortex. Blood 5-HT levels were determined from whole blood, not platelet-poor plasma, collected from the central vein. We found that blood 5-HT levels showed a significant augmentation whenever brain 5-HT levels were significantly elevated after the administration of 5-HTP in those rats with the abdominal surgical procedures. This elevation was abolished after pretreatment with a selective serotonin reuptake inhibitor (fluoxetine; 10 mg/kg i.v.), although brain 5-HT levels remained augmented. These results indicate that augmented brain 5-HT can cross the BBB through the 5-HT transporter from the brain to the circulating blood.

UI MeSH Term Description Entries
D008297 Male Males
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin
D017551 Microdialysis A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.

Related Publications

Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
December 2003, Annals of the New York Academy of Sciences,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
January 2014, Fluids and barriers of the CNS,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
December 1999, Neuroscience letters,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
January 1981, Indian journal of physiology and pharmacology,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
December 1997, The Journal of clinical investigation,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
June 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
May 1997, Oncology (Williston Park, N.Y.),
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
November 2007, Peptides,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
January 2005, The Lancet. Neurology,
Yasushi Nakatani, and Ikuko Sato-Suzuki, and Naohisa Tsujino, and Akane Nakasato, and Yoshinari Seki, and Masaki Fumoto, and Hideho Arita
January 1993, Brain research bulletin,
Copied contents to your clipboard!